Cidara shareholders OK doubling authorized shares to 100M and adding 2.88M shares to equity plan

Cidara Therapeutics, Inc.

Shareholders approved certificate amendment to increase authorized common shares from 50M to 100M, effective June 18, 2025.
2024 Equity Incentive Plan amended to increase share reserve by 2,880,000 shares; approved by stockholders.
Elected Jeffrey Stein, Bonnie Bassler, and Ryan Spencer as Class I directors for terms expiring at 2028 annual meeting.
Ratified Ernst & Young as independent auditor for FY2025; advisory say-on-pay passed.
Voting results: Charter amendment 13,042,275 for, 97,601 against; Equity plan 7,791,328 for, 3,033,052 against.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Cidara Therapeutics, Inc.: Increased authorized shares of common stock from 50,000,000 to 100,000,000 (effective 2025-06-18).

Change: charter amendment
Effective: 2025-06-18

Exact text from the filing

The increase in the authorized number of shares of Common Stock was effected pursuant to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on June 18, 2025 and was effective as of such date.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001610618-25-000072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.